Depuy Orthopaedics Launches Significant Enhancements To Its Sigma(R) Knee Product Portfolio

DePuy Orthopaedics, Inc., a global leader in
devices for joint replacement, announced the launch of new products in its portfolio of
Sigma® Knee products that offer surgeons the ability to select from a wide range of instruments
and implants based on a spectrum of patient needs and their own surgical preferences.


"The launch of these new Sigma Knee products signals a new wave of innovation that will have
significant effects on patient care," said David Floyd, President, DePuy Orthopaedics, Inc.
"These significant enhancements to the Sigma Knee group are the beginning of a new era of
products and solutions designed to offer high performance instrumentation, customization,
quicker recovery, and longer-term durability for the wide range of patients seeking knee
replacement today."


DePuy Orthopaedics made the announcement at the 75th Annual Meeting of the American Academy
of Orthopaedic Surgeons (AAOS), where it will showcase these new products, including Sigma
High Performance instruments, a new line of instruments designed to enhance procedure efficiency,
surgical precision and flexibility. Designed for contemporary knee surgery, the High Performance
Instruments adapt to a surgeon's specific surgical technique, including computer assisted surgery
and manual surgery, with both minimally invasive and traditional open approaches. Sigma High
Performance instruments were developed with a compact design to allow for smaller incisions and
are soft-tissue friendly to reduce surgical trauma. This is DePuy Orthopaedics' largest introduction
of instrumentation in a decade.


"Sigma High Performance Instruments are the most advanced instrumentation we have ever
developed, and the initial feedback from surgeons who've already used the instruments is
extremely positive. These instruments will further contribute to the excellent results seen with
our Sigma Knee implants," said Tom Lavery, Vice-President Marketing, Knees.
Also at AAOS DePuy Orthopaedics is introducing into the Sigma Knee product group the Sigma
CR Porocoat Femur, a cement-less fixation femoral component that contains a porous coating
conducive to deep bone ingrowth and better long-term fixation of the implant and the Sigma PS
Femur, designed to provide today's high demand patients with enhanced function from gait to
deep flexion activities, and the next generation in computer assisted knee software, Ci™ Essential
Knee.


DePuy will introduce additional Sigma Knee products and services over the next 18 months.
The Sigma Knee will also be part of a consumer education campaign called Sigma -- My knee.
My life™. This campaign will encourage patients to talk with their surgeons about which Sigma
knee replacement system will best fit their lifestyle and activity level. For more information visit
kneereplacement.


About Knee Replacement















According to the AAOS more than 500,000 total knee replacements are performed in the U.S.1
The AAOS notes that more joint replacement surgeries are performed on the knee than on any
other joint. In a total knee replacement, the knee is replaced by prostheses made of metal alloys,
high-grade plastics and polymeric materials. Most of the other structures of the knee remain
intact. Knee replacement surgery is generally recommended for patients with severe knee pain
and disability caused by damage to cartilage from rheumatoid arthritis, osteoarthritis or trauma.
It is highly successful in relieving pain and restoring joint function.
The performance of knee replacements depends on age, weight, activity level, and other factors.
There are potential risks and recovery takes time. People with conditions limiting rehabilitation
should not have this surgery. Only an orthopaedic surgeon can tell if knee replacement is right
for a patient.


About DePuy Orthopaedics, Inc.


DePuy Orthopaedics, Inc., a Johnson & Johnson company, is advancing the standard of
orthopaedic patient care, with a focused commitment to help surgeons achieve excellence in
surgical practice. The company designs, manufactures and distributes orthopaedic devices and
supplies including hip, knee, extremity, trauma, cement, orthobiologics, and operating room
products. As a global leader in joint replacement products, DePuy Orthopaedics is committed to
Restoring the Joy of Motion® for patients whose mobility is restricted by severe osteoarthritis or
other debilitating injury. For more information about DePuy Orthopaedics, Inc., visit the
company's Web site depuyorthopaedics.


This press release contains "forward-looking statements" as defined in the Private Securities
Litigation Reform Act of 1995. These statements are based on current expectations of future
events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize,
actual results could vary materially from Johnson & Johnson's expectations and projections.
Risks and uncertainties include general industry conditions and competition; economic
conditions, such as interest rate and currency exchange rate fluctuations; technological advances
and patents attained by competitors; challenges inherent in new product development, including
obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws
and regulations; and trends toward health care cost containment. A further list and description of
these risks, uncertainties and other factors can be found in Exhibit 99 of the Company's Annual
Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as
well as subsequent filings, are available online at sec, jnj or on request from
Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking
statements as a result of new information or future events or developments.


Reference:


"Facts on Knee Replacements," American Academy of Orthopaedic Surgeons, 2005.


DePuy Orthopaedics